| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Join Mayo Clinic Laboratories BioPharma Diagnostics to learn how a collaboration equips you with an end-to-end laboratory testing solution for your clinical trial needs. During meetings and events, BioPharma Diagnostics experts are available to meet with attendees to discuss how our capabilities and data can propel biopharmaceutical and clinical research initiatives. See our upcoming events.
Upcoming events
July 28–Aug. 1: Association for Diagnostics & Laboratory Medicine, Chicago
Learn how our in vitro diagnostic-specific services support medical device, biopharma, and diagnostic companies through analytical validation of new assays and devices in compliance with CAP/CLIA requirements. We facilitate access to Mayo Clinic Laboratories’ core competencies, including analytical validation services, access to biospecimens, and assay development.
July 28–Aug. 1: Alzheimer’s Association International Conference, Philadelphia
We’ll highlight how our robust offerings in the Alzheimer’s disease and dementia testing space, including established and emerging cerebrospinal fluid and plasma biomarkers, can help propel scientific breakthroughs. Our cutting-edge options to assess for neurodegeneration and brain amyloid pathology can help drive development of new treatments for Alzheimer’s disease and other types of dementia.
Oct. 28–29: Biomarker and Precision Medicine US Congress, San Diego
During this event we will discuss how our in vitro diagnostic-specific services support partners with analytical validation of new assays that accelerate diagnosis, support precision medicine, and improve outcomes. Our flexible lab environment provides resources needed for assay development, validation projects, sample acquisition, and co-development opportunities.
Nov. 6–10: Society for Immunotherapy of Cancer Annual Meeting, Houston
Learn how our innovative and advanced oncology offerings can assist partners with their clinical trial needs. In addition to our clinically available tests, you can access oncological testing for clinical trials and be among the first to use up-and-coming tests currently in development.
We offer collaborators:
Highlights
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild cognitive impairment or early dementia. Positive test results can confirm amyloid beta pathology and facilitate access to disease-modifying therapies.
Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' GABA-A receptor antibody assay aids diagnosis of this serious but treatable condition.
In this “Hot Topic,” Divyanshu Dubey, M.B.B.S., associate professor of laboratory medicine and pathology and neurology at Mayo Clinic, discusses various clinical and paraclinical features of autoimmune encephalitis, autoimmune seizures, and epilepsy.
Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' multigene panel helps identify the cause of hereditary ataxia. Precise diagnosis of this complex movement disorder helps guide patient treatment and family screening.
In this month's "Hot Topic," Eoin Flanagan, M.B., B.Ch., reviews the recent diagnostic criteria for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD).
Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the condition — or increase the risk of developing it.
Nicole Boczek, Ph.D., and Sarah Barnett, M.S., CGC, explain how Mayo Clinic Laboratories' whole genome sequencing provides comprehensive information for rapid diagnosis of hereditary disorders.
In this month's "Hot Topic," Eoin Flanagan, M.B., B. Ch., discusses the important issue of autoimmune encephalitis misdiagnosis and identifies red flags that be useful in clinical practice to suggest alternative diagnoses and highlight antibodies that sometimes cause confusion.